 |
|
COMMENTS & OPINIONS
Notice of Redundant Publication: "Transdermal Rotigotine: Double-blind, Placebo-Controlled Trial in Parkinson Disease" (Arch Neurol. 2007;64[5]:676-682)—Reply
Joseph Jankovic, MD;
Ray L. Watts, MD;
Wayne Martin, MD;
Babak Boroojerdi, MD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
We respectfully but strongly disagree with Dr Rosenberg's perception that the 2 cited articles are redundant. We welcome the opportunity to respond to his letter and, in the limited space allowed, explain why the 2 papers are clearly different. While the original article reported the primary efficacy and safety results of the SP 512 Transdermal Rotigotine Phase 3 Pivotal Clinical Trial in Early Parkinson's Disease,1 the second article focused on the secondary outcome variables and plasma pharmacokinetics of rotigotine administered once daily via a novel transdermal delivery system.2 In our recent communications to Dr Rosenberg, we explained that the results of this important study and the many outcome variables along with unique pharmacokinetic data were too extensive to report in a single article submitted to Neurology. Therefore, in the Archives paper,2 we reported primarily . . . [Full Text of this Article] AUTHOR INFORMATION
RELATED LETTER
Notice of Redundant Publication: "Transdermal Rotigotine: Double-blind, Placebo-Controlled Trial in Parkinson Disease" (Arch Neurol. 2007;64[5]:676-682)
Roger Rosenberg
Arch Neurol. 2007;64(12):1800-1801.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Transdermal Rotigotine: Double-blind, Placebo-Controlled Trial in Parkinson Disease
Joseph Jankovic, Ray L. Watts, Wayne Martin, Babak Boroojerdi, and for the SP 512 Rotigotine Transdermal System Clinical Study Group
Arch Neurol. 2007;64(5):676-682.
ABSTRACT
| FULL TEXT
|
